Literature DB >> 15289292

Mutual amplification of apoptosis by statin-induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells.

Martin Werner1, Julia Sacher, Martin Hohenegger.   

Abstract

Besides their cholesterol-lowering effect, 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors (statins) show antiproliferative behaviour, which has been suggested as a promising anticancer strategy. However, the signalling cascades leading to statin-induced death of cancer cells are poorly characterized. Here we show that statins activate the mitochondrial pathway of apoptosis in rhabdomyosarcoma RD cells via translocation of Bax from the cytosol to mitochondria. The prototypical representative of statins, simvastatin, induced consecutive activation of caspase 9 and 3 in a concentration-dependent manner. The permeability transition pore inhibitor bongkrekic acid was capable of completely preventing simvastatin-induced caspase 9 and 3 activity, corroborating the mitochondrial pathway of apoptosis as the sole mechanism of statin action. Alternative pathways via death receptors, that is, caspase 8 or calpain activation, were not triggered by simvastatin. Simvastatin-treated RD cells could be completely rescued from apoptosis by the co-application of mevalonic acid, indicating that deprivation of cholesterol precursors is essential for statin-induced apoptosis. However, pretreatment with subthreshold concentrations of simvastatin was sufficient to augment doxorubicin toxicity via the mitochondrial apoptotic machinery. Moreover, the presence of doxorubicin increased the potency of simvastatin to trigger caspase activation. Taken together, these data highlight the therapeutic anticancer potential of statins and their additivity and mutual sensitization, in combination with doxorubicin in human rhabdomyosarcoma cells. British Journal of Pharmacology (2004).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289292      PMCID: PMC1575923          DOI: 10.1038/sj.bjp.0705928

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  44 in total

Review 1.  Calpain and caspase: can you tell the difference?

Authors:  K K Wang
Journal:  Trends Neurosci       Date:  2000-01       Impact factor: 13.837

Review 2.  Regulation of the mevalonate pathway.

Authors:  J L Goldstein; M S Brown
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

3.  Cell cycle-specific effects of lovastatin.

Authors:  M Jakóbisiak; S Bruno; J S Skierski; Z Darzynkiewicz
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

Review 4.  The ADP-ATP translocation in mitochondria, a membrane potential controlled transport.

Authors:  M Klingenberg
Journal:  J Membr Biol       Date:  1980-09-30       Impact factor: 1.843

5.  Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin.

Authors:  K Keyomarsi; L Sandoval; V Band; A B Pardee
Journal:  Cancer Res       Date:  1991-07-01       Impact factor: 12.701

6.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

7.  Lovastatin causes sensitization of HeLa cells to ionizing radiation-induced apoptosis by the abrogation of G2 blockage.

Authors:  G Fritz; C Brachetti; B Kaina
Journal:  Int J Radiat Biol       Date:  2003-08       Impact factor: 2.694

8.  Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines.

Authors:  S Tomek; W Koestler; P Horak; T Grunt; T Brodowicz; I Pribill; J Halaschek; G Haller; C Wiltschke; C C Zielinski; M Krainer
Journal:  Eur J Cancer       Date:  2003-06       Impact factor: 9.162

Review 9.  Serum cholesterol and cancer risk: an epidemiologic perspective.

Authors:  S B Kritchevsky; D Kritchevsky
Journal:  Annu Rev Nutr       Date:  1992       Impact factor: 11.848

10.  Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses.

Authors:  Henry Y Li; Frederick R Appelbaum; Cheryl L Willman; Richard A Zager; Deborah E Banker
Journal:  Blood       Date:  2002-12-27       Impact factor: 22.113

View more
  23 in total

Review 1.  Statin therapy in cardiovascular diseases other than atherosclerosis.

Authors:  Dominique Beaudry; Kenneth E Stone; Suzanne Wetherold; John Hemphill; Dat Do; John McClish; Robert Chilton
Journal:  Curr Atheroscler Rep       Date:  2007-01       Impact factor: 5.113

2.  Autocrine amplification loop in statin-induced apoptosis of human melanoma cells.

Authors:  C Minichsdorfer; M Hohenegger
Journal:  Br J Pharmacol       Date:  2009-06-25       Impact factor: 8.739

Review 3.  Novel Indications for Commonly Used Medications as Radiation Protectants in Spaceflight.

Authors:  Mark F McLaughlin; Dorit B Donoviel; Jeffrey A Jones
Journal:  Aerosp Med Hum Perform       Date:  2017-07-01       Impact factor: 1.053

4.  Simvastatin potentiates doxorubicin activity against MCF-7 breast cancer cells.

Authors:  Benjaporn Buranrat; Wanwisa Suwannaloet; Jarinyaporn Naowaboot
Journal:  Oncol Lett       Date:  2017-08-21       Impact factor: 2.967

5.  Cholesterol effects on BAX pore activation.

Authors:  Eric Christenson; Sean Merlin; Mitsu Saito; Paul Schlesinger
Journal:  J Mol Biol       Date:  2008-06-20       Impact factor: 5.469

6.  Interactions between cell death induced by statins and 7-ketocholesterol in rabbit aorta smooth muscle cells.

Authors:  W Martinet; D M Schrijvers; J-P Timmermans; H Bult
Journal:  Br J Pharmacol       Date:  2008-05-12       Impact factor: 8.739

7.  Cytotoxic evaluation of doxorubicin in combination with simvastatin against human cancer cells.

Authors:  H Sadeghi-Aliabadi; M Minaiyan; A Dabestan
Journal:  Res Pharm Sci       Date:  2010-07

8.  Autocrine secretion of 15d-PGJ2 mediates simvastatin-induced apoptotic burst in human metastatic melanoma cells.

Authors:  Christine Wasinger; Martin Künzl; Christoph Minichsdorfer; Christoph Höller; Maria Zellner; Martin Hohenegger
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

9.  Anthracyclins Increase PUFAs: Potential Implications in ER Stress and Cell Death.

Authors:  David Balgoma; Fredrik Kullenberg; Carlemi Calitz; Maria Kopsida; Femke Heindryckx; Hans Lennernäs; Mikael Hedeland
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

10.  Simvastatin-induced compartmentalisation of doxorubicin sharpens up nuclear topoisomerase II inhibition in human rhabdomyosarcoma cells.

Authors:  Martin Werner; Bihter Atil; Evelyn Sieczkowski; Peter Chiba; Martin Hohenegger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-07       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.